Table 3. Multiplex assay performance characteristics including the kit manufacturer’s calibration range, and stated lower limit of quantification (LLOQ), empirically derived LLOQ and percent recovery in serum and saliva.
| Panel | Analyte | CalibrationRange | Unit | KitLLOQ | EmpiricalLLOQ | Serum %Recovery | Saliva % Recovery |
| Bone | Insulin | 0.08–250 | ng/mL | 0.05 | * | 125 | 184 |
| Leptin | 0.016–300 | ng/mL | 0.12 | * | 7 | 59 | |
| OPG | 0.50–8500 | pg/mL | 1.42 | * | 156 | 36 | |
| PTH | 0.55–9800 | pg/mL | 0.3 | * | 88 | 38 | |
| MMP | MMP-1 | 9.13–6800 | pg/mL | 6.3 | 37 | 58 | 42 |
| MMP-2 | 9.7–55,000 | pg/mL | 7.5 | 400 | ND | 102 | |
| MMP-8 | 12.5–80,000 | pg/mL | 5.0 | * | 20 | ND | |
| MMP-9 | 8.1–47,900 | pg/mL | 11.0 | * | 107 | ND | |
| Obesity | Adiponectin | 0.37–270 | ng/mL | 0.0198 | * | ND | 92 |
| CRP | 0.03–21 | ng/mL | 0.0019 | * | ND | 56 | |
| 10 Plex | GM-CSF | 0.20–387 | pg/mL | <1.0 | 1.1 | 72 | 56 |
| IFNγ | 0.10–145 | pg/mL | <1.0 | * | 51 | 168 | |
| IL-10 | 0.20–485 | pg/mL | <1.0 | * | 117 | 8 | |
| IL-1β | 0.10–211 | pg/mL | <1.0 | * | 46 | 85 | |
| IL-2 | 0.10–273 | pg/mL | <1.0 | * | 63 | 128 | |
| IL-4 | 0.20–417 | pg/mL | <1.0 | * | 54 | 112 | |
| IL-5 | 0.20–393 | pg/mL | <1.0 | * | 168 | 70 | |
| IL-6 | 0.10–133 | pg/mL | <1.0 | * | 94 | 116 | |
| IL-8 | 0.20–356 | pg/mL | <1.0 | * | 107 | ND | |
| TNFα | 0.10–212 | pg/mL | <1.0 | * | 19 | 83 | |
| 4-Plex | MCP-1 | 6.2–2100 | pg/mL | 0.5 | * | ND | ND |
| TNFα | 2.3–4500 | pg/mL | 0.3 | * | 100.4 | 93.24 |
ND, not determined as baseline sample level was>highest calibrator.
*
all replicate samples achieved CV <20% and therefore the manufacturer’s stated LLOQ is accepted.